REPRISE trial presented as a late breaking abstract at American Society of Nephrology (ASN) Kidney Week 2017
November 4, 2017
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced detailed results from the Phase 3 REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). Trial results showed that tolvaptan showed greater reduction on the primary endpoint, the rate of change in estimated glomerular filtration rate (eGFR) compared to placebo.Read More
Health Canada issues a Notice of Compliance for ABILIFY MAINTENA, approving a new indication for the maintenance monotherapy treatment of bipolar I disorder in adult patients.
November 2, 2017
Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension), approving a new indication for the maintenance monotherapy treatment of bipolar I disorder in adult patients.Read More
Health Canada Approves Otsuka and Lundbeck’s REXULTI™ (brexpiprazole) as a Treatment for Schizophrenia in Adults
February 16, 2017
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for REXULTI™ (brexpiprazole) for the treatment of schizophrenia in adults. REXULTI™ was discovered by Otsuka and co-developed with Lundbeck. It will be co-marketed by the two companies and is expected to become commercially available in Canada this spring.Read More
2250 Alfred-Nobel Boulevard,
Copyright Otsuka 2018. All rights reserved.
The information contained on this website is only intended for use by Canadians.